


Generative AI, multi-scale modeling and simulations with experiments-in-the-loop for biotherapeutic design



Arvind Ramanathan/ ramanathana@anl.gov

Argonne National Laboratory/ University of Chicago Consortium for Advanced Science and Engineering (CASE)/ Northwestern-Argonne Institute for Science and Engineering (NAISE)

https://ramanathanlab.org/

https://github.com/ramanathanlab

Accelerating discovery using AI assistants

Study Extraction, integration and reasoning with knowledge at scale Question Tools help identify new questions based on needs and gaps in knowledge

Report

Machine representation of knowledge leads to new hypotheses and questions

https://doi.org/10.1038/s41524-022-00765-z

Hypothesize

Generative models automatically propose new hypotheses that expand the discovery space

Test

Robotic labs automate experimentation and bridge digital models and physical testing

Assess

Pattern and anomaly detection is integrated with simulation and experimentation to extract new insights

Autonomous Discovery @Argonne

The vision

- A system that starts with a high-level description of a hypothesis and autonomously carries out computational and experimental workflows to confirm or reject that hypothesis
- Use of AI in robotics and simulations to close the loop on planning, execution, and analysis of experiments

Builds on


- Al approaches to planning (multiple steps),
 and integration of results, causality, etc.
- Machine learning/simulation to design and predict properties and outcomes
- Automation of experimental protocols (robotic steps and workflows)
- Active Learning or RL for selection of next experimental targets, etc.

ARTIFICIAL INTELLIGENCE GUIDED, ROBOTICALLY EXECUTED EXPERIMENTS




https://github.com/anl-sdl/
https://www.cs.uchicago.edu/~rorymb/

Agentic implementation of laboratory workflows




Disordered proteins span over 30% of the human proteome and are important drug targets

- Proteins without a stable tertiary structure:
 - High flexibility
 - Adaptable binding interfaces
- 65% of these proteins are involved in diseases:
 - Cancer
 - Neurodegenerative
 - Cardio-vascular
 - Diabetes
- We want to largely target the "undruggable" genome as part of this project
- This is not restricted to just human genomes; we are looking at viral, bacterial, fungal pathogens (for infectious diseases)





Uversky, V., Oldfield, C., Dunker, K., (2008) Annu. Rev. Biophys., 37: 215-246 Liu, J., Faeder, J.R., Camacho, C.J., (2009) Proc. Natl. Acad. Sci. USA, 106 (47): 19189 Dyson, J.H., Wright, P.E., (2015) Nat. Rev. Mol. Cell Biol.,

Background: Biomolecular dynamics spans multiple length- and time-scales...



... current AI ecosystem of tools are not biophysically aware






AlphaFold3: Sometimes remarkable results have interesting failure modes...

AlphaFold3: https://www.nature.com/articles/s41586-024-07487-w

DiffDock/NeuralPlexer: none of them able to associate proteinprotein interactions or proteinligand interactions accurately

DiffDock: https://arxiv.org/html/2402.18396v1
NeuralPlexer:

https://www.nature.com/articles/s42256-024-00792-z



BioEmu: ~200 ms of simulation training time, but applications are still limited

Scalable emulation of protein equilibrium ensembles with generative deep learning

Sarah Lewis, et al, , Cecilia Clementi, Frank Noé


https://doi.org/10.1101/2024.12.05.626885

Outline

- Can we use AI to effectively learn biophysically relevant features automatically?
 - DeepDriveMD: Accelerating biomolecular simulations with surrogate models
 - StreamAI-MD: Heterogeneous computing to accelerate simulation workflows
- Can we use AI to effectively accelerate length- and time-scales accessible to MD simulations to bridge multi-modal experimental techniques?
 - Intelligent Resolution: Integrating cryo-EM with X-ray crystallography using AIdriven simulation workflows
 - AA2CG2AA: Agentic AI to allow all-atom to coarse-grained to all-atom simulation campaigns
- Can we use AI to guide experimental campaigns for enabling biological systems design?
 - Experiments in loop for designing better enzymes by integrating multi-modal data
 - Using AI to simulate actual labs


Standard simulation approaches face significant data movement and parallel analytics challenges


Need for interleaving analytics (AI/ML) + Simulations (HPC)




- Large simulations generate > O(100 TB) of data
- Humanly impossible to peek into "biologically" interesting events!
- http://deepdrivemd.github.io
- Ma, Lee, et al. PARCO (2019)
- Lee, Ma, et al. Workshop on Deep Learning on Supercomputers, Supercomputing (2019)

Ensemble Toolkit Workflow







Deep learning can identify reaction coordinates for complex conformational transitions



How does the spike protein open to fuse with human cells?



Low-dimensional latent representation learned by convolutional variational autoencoder




T Sztain*, SH Ahn*,...LTC, R Amaro. Nat. Chem. (2021).

A Trifan, T Sztain, et al, LTC, A. Ramanathan, R. Amaro IJHPCA (2020, 2021)

A. Ramanathan, et al Current Opinion in Structural Biology (2019)

D. Bhowmik, et al, BMC Bioinformatics (2017)


DeepDriveMD enables 4-fold acceleration of sampling effectiveness for FSD-EY ($\beta\beta\alpha$) folding



- Embedding states into the VAE latent space and clustering with k-means keeps a constant definition of the number of states sampled enabling fair comparison between simulations
- The ML + RMSD strategy reaches 80%
 sampling at least 4 fold faster than Anton-1
 simulations
- Integrating with weighted ensemble techniques we can get access to kinetics

Note: Uncertainty from 10 trials is shown in light, red


Bridging ThetaGPU + CS-1 with Stream-AI-MD




Accelerating MD simulations with surrogate models provides ~10³⁻⁵ speedup for protein systems

Table 6. F-MSE on AdK equilibrium trajectory dataset.

Linear	RF	MPNN	EGNN	EGHN EGNO	EGHNO	Blocks
2.890	2.846	2.322	2.735	2.034 2.231	1.801	






Minkai Xu, Jiaqi Han, Aaron Lou, Jean Kossaifi, Arvind Ramanathan, Kamyar Azizzadenesheli, Jure Leskovec, Stefano Ermon, Anima Anandkumar

Outline

- Can we use AI to effectively learn biophysically relevant features automatically?
 - DeepDriveMD: Accelerating biomolecular simulations with surrogate models
 - StreamAI-MD: Heterogeneous computing to accelerate simulation workflows
- Can we use AI to effectively accelerate length- and time-scales accessible to MD simulations to bridge multi-modal experimental techniques?
 - Intelligent Resolution: Integrating cryo-EM with X-ray crystallography using AIdriven simulation workflows
 - AA2CG2AA: Agentic AI to allow all-atom to coarse-grained to all-atom simulation campaigns
- Can we use AI to guide experimental campaigns for enabling biological systems design?
 - Experiments in loop for designing better enzymes by integrating multi-modal data
 - Using AI to simulate actual labs

Continuum ⇔ all-atom simulations: using AI to guide and refine Cryo-electron microscopy data



domain

orientations Interface

potentials

Hierarchical Al Methods for

computational steering

Ensemble Continuum


Simulations (FFEA)

A. Trifan, et al, Intelligent Resolution. IJHPCA (2021)

ensembles of conformational transitions in multimer


complexes (SARS-CoV-2 replication transcription complex)

Multiscale modeling workflows switching between all-atom and coarse-grained representations for CSF1R model - extracellular domain



Full-length membrane-bound CSF1R model

Capturing protein-membrane interactions and complexation



Outline

- Can we use AI to effectively learn biophysically relevant features automatically?
 - DeepDriveMD: Accelerating biomolecular simulations with surrogate models
 - StreamAI-MD: Heterogeneous computing to accelerate simulation workflows
- Can we use AI to effectively accelerate length- and time-scales accessible to MD simulations to bridge multi-modal experimental techniques?
 - Intelligent Resolution: Integrating cryo-EM with X-ray crystallography using AIdriven simulation workflows
 - AA2CG2AA: Agentic AI to allow all-atom to coarse-grained to all-atom simulation campaigns
- Can we use AI to guide experimental campaigns for enabling biological systems design?
 - Experiments in loop for designing better enzymes by integrating multi-modal data
 - Using AI to simulate actual labs

Using the agentic co-scientist to summarize results...

Research cycle complete!
Generated 50 total hypotheses
Completed 30 tournament matches

Top 3 drug repurposing hypotheses:

1. A biologic therapy using a cell-penetrating antibody-peptide conjugate is proposed to target and inhibit the SET domain of WHSC1, leveraging unique structural features of WHSC1 for cancer therapy. (Elo rating: 1258.4)

Content snippet: This hypothesis proposes the development of a biologic therapy comprising a cell-penetrating antibody conjugated to a peptide that specifically binds and inhibits the SET domain of WHSC1. The antibody...

2. The hypothesis proposes a nanobody-based biologic therapy targeting WHSC1 in cancer, utilizing nuclear localization signals and cell-penetrating peptides for specificity and efficient delivery. (Elo rating: 1244.4)

Content snippet: This improved hypothesis proposes the development of a novel biologic therapy using engineered nanobodies fused to a nuclear localization signal (NLS), designed to selectively bind and inhibit the SET...

3. Develop a fusion protein therapy using DARPins and CPP to target WHSC1's SET domain with high specificity and efficient cellular/nuclear delivery. (Elo rating: 1231.3)


Content snippet: This hypothesis proposes the development of a biologic therapy using a bifunctional fusion protein. This fusion protein consists of a designed ankyrin repeat protein (DARPins) targeting the SET domain...

Research overview:

Title: Designing a Novel Biologic Therapy for Targeting WHSC1 in Cancer

Executive summary: This research overview outlines strategies for developing a biologic therapy targeting the SET domain of the WHSC1 protein, a histone methyltransferase implicated in various cancers. The focus is on designing a therapy that is specific, effective, and capable of nuclear penetration, leveraging structural biology techniques, cell-based assays, and in vivo models.

... providing novel (hopefully less hallucinated) insights across diverse data streams




Protein design needs "special" prompts to be effective but lacks clear, direct incorporation of design constraints


"I need a mostly hydrophobic protein with 7 transmembrane alpha-helices that can mediate cell signaling" + Proteins

https://310.ai/

https://www.evolutionaryscale.ai/blog/esm3-release

Hypothesis: Multimodal language models can incorporate experimental observables to constrain the generation of protein sequences






 Preference Optimization as a strategy to balance novelty of sequences vs. design constraints (e.g., GC content, catalytic activity, binding affinities)


Applications

- Enzyme redesign to improve catalytic activity with LLMs
- Antibody design with RF-Diffusion + feedback


Algorithmic innovation: Direct Preference Optimization strategy in two distinct modes aligns generative process w/ experimental data



- Incorporates feedback into the language model via preferences represented via user/ experimental data:
 - Mode 1: Encode user preferences via a classifier trained on experimental fitness datasets
 - Mode 2: Self-alignment where the language models "learns" the preferences via the generative process
- DPO loss function formulated to preferentially weigh 'preferred' samples over 'unpreferred' samples to update model weights
- Scaling of DPO implemented for the reference and policy models using Megatron-Deepspeed framework:
 - fused kernels from NVIDIA's Megatron-LM with the ZeRO optimization and Pipeline parallelism of DeepSpeed
 - FlashAttention-2 to improve throughput of training
 - sequence lengths of 512 and 1024 as the target protein families



MProt-DPO for Malate Dehydrogenase (MDH) improves predicted activity ~3.0 fold increase with preliminary experimental confirmation



- Despite lower sequence similarity, key motifs in the structures are conserved; average sequence lengths 300, median ~25 residues
- 48 variants validated in the laboratory of which 13 sequences exhibit enhanced MDH activity compared to wildtype designs (round 1)

Scaling Mprot-DPO on supercomputers



NVIDIA GH200 GPU 4 GPUs/Node

 Scale across five diverse supercomputing systems, including one cloud platform

Intel Max 1550 GPU

HPE 5S 11 (8 NICs)

200 GB/s

6 GP Systems include GPUs from Nvidia, AMD and Intel

NVIDIA A100 GPU 4 GPUs/Node IB HDR (2 NICs) 50 GB/s

System architected using Infiniband and HPE Slingshot

 Training leverages mixed precision wherein we use FP16 or BF16 (primary compute) together with FP32 (gradients)

deepspeed

AMD MIZOUN OF U 4 GPUs/Node HPE SS 11 (4 NICs) 100 GB/s






INVIDIATITUU GEO 8 GPUs/Node IB NDR (8 NICs) 400 GB/s


... Achieves >1 Exaflops (MP) on each compute resource

		tops (in	, ,
	Aurora	/	
(2)	↓ Leonardo		
/ SI	-		
ker	-		
(to	-		

Leonardo)
Frontier	
	0/ 1
	Leonardo Frontier

System	Nodes	# of GPUs	Sustained EFLOPS (MP)	% Model Flop Utilization (MFU)	Peak EFLOPS (MP)
Aurora	3200	19200	4.11	44.5	5.57
Alps	2060	8240	2.92	41.7	3.16
Frontier	2048	8192	1.06	33.8	1.18
PDX	400	3200	1.29	48.4	1.39





Summary

- Al techniques in the loop can help accelerate therapeutic discovery processes
- We can design novel types of therapeutics with generative models:
 - peptides, antibodies,
 - proteins with non-standard amino-acids,
 - PNA (peptide nucleic acid)
- Self-driving labs is at the intersection of AI + high performance computing + real-life interactions
 - Transforming an entire generation of workforce
- HPC environments are critical resources for generative design:
 - a promptable engine for biologics design
 - inverse design is also a plausible strategy for targeting IDPs



Acknowledgements

Funding

- DOE BER AI Pilot projects
- O CEPI
- O DOE ASCR MEDAL Project
- ARPA-H

Computing Time

- Argonne Leadership Computing (Theta/ Theta-GPU/ Al-testbed)
- INCITE
- Cerebras/Nvidia

Data/ Code/ Models

- https://github.com/ramanathanlab/genslm
- Access to model weights will also be available via API

Colleagues

- Richard Scheuermann
- James Olds
- Wesley Scott
- Anda Trifan
- Ashka Shah
- Ozan Gokdemir
- Mike Tynes

Questions/Comments

ramanathana@anl.gov